Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 295 Shares

Key Points

• Natera insider John Fesko sold 295 shares at an average price of $267.99, generating $79,057.05. The Rule 10b5-1 transaction was intended to cover tax withholding on vested equity awards, leaving him with 183,774 shares.
• Natera shares traded down 0.2% to $274.58, near their 52-week high of $288.04, with a market capitalization of approximately $39.32 billion.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $267.83 price target; institutional investors own approximately 99.9% of the company.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 295 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $267.99, for a total transaction of $79,057.05. Following the completion of the sale, the insider owned 183,774 shares in the company, valued at approximately $49,249,594.26. This trade represents a 0.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $236,539.17.
• On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $203,703.18.
• On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92.

Natera Trading Down 0.2%

Shares of NASDAQ NTRA traded down $0.61 during midday trading on Wednesday, reaching $274.58. The company's stock had a trading volume of 1,128,660 shares, compared to its average volume of 1,104,859. Natera, Inc. has a one year low of $135.75 and a one year high of $288.04. The company has a market cap of $39.32 billion, a price-to-earnings ratio of -168.45 and a beta of 1.51. The company has a 50 day moving average price of $251.03 and a 200 day moving average price of $222.85.

Institutional Investors Weigh In On Natera

Hedge funds have recently bought and sold shares of the business. Reflection Asset Management acquired a new stake in Natera during the 4th quarter worth about $29,000. Elevation Wealth Partners LLC purchased a new stake in shares of Natera in the second quarter worth approximately $30,000. Palladiem LLC acquired a new stake in shares of Natera during the fourth quarter worth approximately $31,000. Horizon Investments LLC purchased a new position in Natera during the third quarter valued at approximately $32,000. Finally, International Assets Investment Management LLC increased its stake in Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company's stock valued at $35,000 after buying an additional 97 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on NTRA. William Blair assumed coverage on Natera in a report on Tuesday, April 14th. They issued an "outperform" rating on the stock. Canaccord Genuity Group lifted their target price on Natera from $285.00 to $330.00 and gave the stock a "buy" rating in a report on Tuesday, July 14th. Robert W. Baird set a $265.00 target price on Natera in a research report on Friday, May 8th. The Goldman Sachs Group started coverage on Natera in a report on Friday, June 5th. They set a "neutral" rating and a $245.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on Natera from $260.00 to $265.00 and gave the stock an "overweight" rating in a research note on Friday, May 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source